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Abstract 
     In cancer treatment, the radiation can make a more concentrated attack on 
cancer cells, and molecular target drugs, which can snipe at cancer cells at a 
molecular level appeared as anticancer drugs, and the surgery is tried to be less 
aggressive and keep the function of living in the human medicine. However, on the 
which are patients for whom there is no treatment anymore when a standard 
treatment becomes less effective. In order to overcome such situation, various new 
treatments including immunotherapy, gene therapy and hyperthermia are 
establishing. 
     In the small animal medicine represented by dogs and cats, which almost 
imitates the human medicine, it seems that the treatment of animals depends heavily 
treatments. In addition, because of geographical or economic factor, almost all 
owners do not seem to receive the benefit of standard treatments. It is real that there 
is no doubt that the small animal medicine also needs to fundamentally improve 
methods of cancer treatment as well as the human medicine and this improvement 
will have a significant positive impact on human society including animal owners.  
     We have sought a development of new cancer treatment and an establishment 
of it. In that process, we focused on hyperthermia with few side effects and 
photodynamic therapy as reported before. However, hyperthermia was not a popular 
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treatment in veterinary field, because it was a combination treatment with standard 
treatments rather than single, it needed expensive equipment, and we could not apply 
basic data for it though it had a history in human medicine. Furthermore, 
photodynamic therapy also did not be used widely because of less supply and high 
cost of sensitizers. Then, we focused on Indocyanine Green (ICG) used basically and 
clinically also in human medicine, which was safe and low in cost. ICG reacts to light 
and has a hyperthermic effect and photodynamic effect. We devised and aimed at a 
clinical application of Photodynamic Hyperthermia (PHT) using ICG as sensitizer and 
near infrared light (600-800nm). In addition, based on that an anticancer effect was 
enhanced by hyperthermia, we revised Photodynamic Hyperthermal Chemotherapy 
(PHCT) combined PHT and anticancer drugs.  
     In the chapter , on the basis of antitumor effect in PHT reported in vitro , we 
used a tumor-bearing mouse model and made it obvious that antitumor effect was 
recognized in vivo.  
     In the chapter , we applied PHCT made by adding local anticancer drugs to 
PHT in 16 cases of dogs and cats with malignant soft tissue sarcoma. It had been 
considered that malignant soft tissue sarcoma recurred locally very often and 
radiation was the only way to prevent recurrence of it. However these results suggest 
that PHCT decreases the risk of recurrence.  
     From these studies, it is considered that new treatment options for superficial 
solid cancers will increase in the small animal medicine.
General Introduction 
General Introduction 
     Recently, the life span of companion animals becomes longer because of the 
vaccination against various infectious diseases, the improvement of eating and 
environment, etc, and in addition, the development of veterinary medicine. As a result, 
various illnesses related to aging are increasing. In particular, cancer is one of serious 
problems.  
     These days, it is said that cancer became a curable disease with an advance in 
cancer treatment. The outcome from treatment is certainly improving in human 
medicine field. However, the number of deaths due to cancer is going on increasing 
and eight hundred thousand people a year get cancer in Japan. One of out three 
people, about four hundred thousand people a year, dies from cancer in Japan, where 
one of out five people died from cancer twenty years ago. On the contrary, the rate of 
animals dying from cancer is getting higher in the small animal medicine field than that 
in the human medicine field. 
     In the case of dogs, about 40% of dogs aged 10 or older die from cancer. Due to 
the changings of their diet and rearing environment and the stress associated with 
such changings, diseases are getting diversified. As a result, most diseases such as 
malignant tumor, heart disease and diabetes, which occur in humans started to 
develop in rearing small animals. Especially cancer is the leading cause of death. 
     In the small animal medicine field represented by dogs and cats, which almost 
imitates the human medicine field, cancer treatment is also standard treatment 
including surgery, chemotherapy and radiotherapy. However, it is hard that we treat all 
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cases by these treatments. The treatment of animals depends heavily on their 
ntention, and all animals therefore cannot undergo standard treatments. In 
addition, because of geographical or economic factor, almost all owners do not seem 
to receive the benefit of standard treatments. It is real that there are a lot of animals 
and the
small animal medicine field also needs to fundamentally improve methods of cancer 
treatment as well as the human medicine and this improvement will have a significant 
positive impact on human society including animal owners. Therefore it is necessary 
to develop a new treatment that is safe, simple and applicable. 
     We noticed that indocyanine green (ICG) generates heat in response to the light 
near 800 nm (hyperthermia) (Chen et al., 1995a; Chen et al., 1995b; Chen et al., 
1996; Liu et al., 2002). ICG was developed as a drug to promote liver and bile duct 
function, and it has been used medically since 1956 (Cherrick et al., 1960). This drug 
is safe, and the principle advantage of ICG is low toxicity (Hope-Ross et al., 1994). In 
particular, ICG is widely used in ophthalmology for hyperthermia therapy with an 
808-nm diode laser to treat chorioretinopathy (Dzurinko et al., 2004). ICG is also used 
in sentinel biopsies (Hirche et al., 2010; Hojo et al., 2010). 
     Hyperthermia is used as a combined treatment with radiotherapy and 
chemotherapy because cell-killing effect is recognized at a temperature adaptable to 
a human body, tumor tissues are easier to be heated than normal tissues, and 
temperature-sensitive enhances when intracellular pH decreases (Dewey et al., 1977; 
Jähde & Rajewsky, 1982; Storm et al., 1979). 
     Hyperthermia is not a common treatment in the veterinary field because the 
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device is expensive and little fundamental data are available. On the other hand, there 
are reports of PDT being used to treat canine and feline spontaneous tumors, and the 
efficiency of this technique has been recognized (Dougherty et al., 1981; Okamoto et 
al., 2005; Osaki et al., 2009; Peaston et al., 1993; Reeds et al., 2004; Roberts et al., 
1991; Tanabe et al., 2004). However, the photosensitizer for PDT is very expensive 
and a special diode laser is required. Therefore, PDT is rarely used in the veterinary 
field. 
     Some reports have suggested that ICG induces the formation of oxygen radicals 
(Abels et al., 1998; Bäumler et al., 1999; Bozkulak et al., 2009; Diven et al., 1996; 
Mamoon et al., 2009). Most of these reports are from in vitro studies of different 
human cell lines. Bozkulak et al. reported that ICG with near-infrared light (809 nm, 60 
mW/cm2, 24 J/cm2) is very effective in treating human breast cancer cells (Bozkulak et 
al
authors concluded that ICG is a new photosensitizer. Hirano et al. was the first to 
demonstrate that ICG induces the formation of oxygen radicals in response to 
irradiation with light of a wavelength of 600-800 nm (Hirano et al., 2006). 
     On the basis of these, we developed a new cancer treatment by using ICG and 
the broadband light source apparatus. This is a combined treatment with 
photodynamic therapy using ICG and hyperthermia. We named this treatment to 
Photodynamic Hyperthemal Therapy (PHT).  
     Previously, we reported that PHT induced morphological cell death and 
inhibition of cell proliferation of murine melanoma cell, B16F10 (Radzi et al., 2012a). 
Furthermore, it was found that PHT induced apoptosis and cell cycle arrest in vitro
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(Radzi et al., 2012b). However, there was no in vivo experimental data of PHT related 
with tumor growth and histological change. 
     In the chapter , on the basis of antitumor effect in PHT reported in vitro, we used 
a tumor-bearing mouse model and made it obvious that antitumor effect was 
recognized in vivo.  
     Anti-tumor drug effects are enhanced by heat (Hahn et al., 1975; Hahn, 1979; 
Marmor, 1979; Newell & Tannock, 1989). Furthermore, tumor tissues have a tendency 
to be acidic (Wike-Hooley et al., 1985). Therefore, we selected bleomycin as an 
anti-tumor drug because it is effective in acidic environments (Hahn et al., 1975). 
Platinum drugs such as cisplatin and carboplatin are also useful anti-tumor drugs. 
     In the chapter , we applied PHCT made by adding local anticancer drugs to 
PHT in 16 cases of dogs and cats with malignant soft tissue sarcoma. It had been 
considered that malignant soft tissue sarcoma recurred locally very often and 
radiation was the only way to prevent recurrence of it. However these results suggest 
that PHCT decreases the risk of recurrence.  
     From these studies, it is considered that new treatment options for superficial 
solid cancers will increase in the small animal medicine.
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Chapter 
Effects of photodynamic hyperthermal therapy with indocyanine green on 
tumor growth in a colon 26 tumor-bearing mouse model 
Abstract 
The present study used indocyanine green (ICG) and a broadband light source 
apparatus [photodynamic hyper-thermal therapy (PHT) group] in order to treat a colon 
26 tumor-bearing mouse model. The other groups were administered either ICG 
alone (ICG group), light alone (light group) or no treatment (control group). Following 
the treatment, tumor growth was measured. Nine days after the treatment, the tumors 
were resected and histological and immunohistological examinations were performed. 
In the PHT group, the growth rates of the tumor tissues were significantly decreased 
compared with those observed in the other groups (P<0.05). The proportion of 
necrotic areas in the PHT and light groups were increased significantly compared with 
those observed in the ICG and control groups. However, there were no significant 
differences between the PHT and light groups. The proportion of Ki-67 in the PHT and 
light groups was less than that observed in the ICG and control groups. The number 
of terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling-positive 
cells in the PHT group was significantly increased compared with that observed in the 
other groups. These data indicate that PHT is effective in vivo and in vitro. 
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1. Introduction 
     The life span of animals has grown longer due to vaccinations for various 
infectious diseases, improvements in food and environment and the development of 
veterinary medicine. As a result, the incidence of various illnesses that are associated 
with aging have been increasing in pet populations. In particular, cancer is a 
significant problem. As in human medicine, there are three major treatments for 
cancer in veterinary medicine, surgery, chemotherapy and radiation. However, it is 
difficult to treat all cases with these therapies. Therefore, it is necessary to develop 
new treatments. 
     Indocyanine green (ICG) generates heat in response to light near a wavelength 
of 800 nm (hyperthermia) (Chen et al., 1995a; Chen et al., 1995b; Chen et al., 1996; 
Liu et al., 2002). Furthermore, ICG generates active oxygen in response to light at 
600-800 nm (photodynamic effect) (Abels et al., 1998; Bäumler et al., 1999; Bozkulak 
et al., 2009; Hirano et al., 2006). The principle advantage of ICG is low toxicity 
(Hope Ross et al., 1994). ICG has become widely used during sentinel biopsies 
(Hirche et al., 2010; Hojo et al., 2010; Ito et al., 2004). Based on this, we developed a 
new cancer therapy, called photodynamic hyperthermal therapy (PHT), using ICG and 
a broadband light source apparatus. We previously reported that PHT induced 
morphological cell death and inhibited the proliferation of the murine B16F10 
melanoma cell line (Radzi et al., 2012a). Furthermore, it has been demonstrated that 
PHT induces apoptosis and cell cycle arrest in vitro (Radzi et al., 2012b). However, 
there are no in vivo experimental data with regard to PHT-related tumor growth and 
histological changes. 
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     The present study aimed to investigate the effects of PHT on tumor growth and 
histological changes using colon 26 tumor-bearing mice in vivo. 
2. Materials and methods 
2.1 Preparation of the tumor-bearing mouse model
     A total of 23 female five-week-old BALB/c mice were purchased from CLEA 
Japan, Inc. (Osaka, Japan). The animals were maintained under conventional 
conditions. The use of these animals and the procedures they underwent were 
approved by the Animal Research Committee of Tottori University. Colon 26 tissue, 
which is of murine colon cancer origin, was transplanted subcutaneously into the 
dorsal regions of the mice. 
     The mice were bred for nine days with free access to food and water, following 
which, the experiments were performed. The mice whose tumors grew to 5 mm in size 
were used in this study. 
2.2 Study design
     The mice (n=23) were divided into four groups that were subjected to light + ICG 
(PHT group; n=8), ICG alone (ICG group; n=5), light alone (light group; n=5) or were 
untreated (control group; n=5). 
     All the treatments were performed at day 0 under general anesthesia with 
inhalation of 5% isoflurane. In the PHT group, 25 mg ICG (Diagnogreen; Daiichi 
Sankyo, Tokyo, Japan) was dissolved in 10 ml saline and adjusted to pH 5.0. A total of 
0.5 ml ICG solution was injected into the tumor tissue, following which, irradiation was 
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performed using a near
output, 5.0 W; 600 1600 nm of output wavelength bands; Tokyo Iken Co., Ltd., Tokyo, 
Japan). Irradiation was performed for 10 min using 20% output so that the distance 
from the tumor to the light source was 3 5 cm. The temperature of the tumor tissue 
and on the tumor surface during irradiation was measured using a digital temperature 
indicator (Anritsu Meter Co., Ltd., Tokyo, Japan) and maintained in a range of 
42.5-
solution was injected without the administration of irradiation. In the light group, 
irradiation was performed under similar conditions to those that were used in the PHT 
group. 
     Following nine days of treatment (day 9), all the mice were sacrificed by 
inhalation of 5% isoflurane followed by cervical dislocation. On days 0 and 9, the 
volume of tumor tissue was calculated by measuring the mediastinum and the 
transverse length, and the depth of the tumor. Based on volumes of the tumor on days 
0 and 9, the tumor growth rate (mm3/day) was calculated as follows: (tumor volume on 
day 9 - tumor volume on day 0)/9. The tumor tissue was removed and fixed in 10% 
buffered formalin. 
2.3 Histological examination 
     The fixed samples were embedded in paraffin and sectioned in a routine 
manner. The sections were stained with hematoxylin and eosin (HE staining) and 
examined immunohistologically for Ki-67 and terminal 
deoxynucleotidyltransferase-mediated dUTP nick end labeling (TUNEL) staining. 
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     For the Ki-67 staining, 3-µm tissue sections were placed on glass slides and 
deparaffinized, then washed with ethanol and water and soaked in 
phosphate-buffered saline (PBS). The sections were autoclaved using 0.01 M citrate 
polyclonal anti-Ki-67 antibodies (1:50; code no. E0468; Dako, Glostrup, Denmark) for 
30 min at room temperature. Subsequent to being washed with PBS, the sections 
were incubated with rat anti-immunoglobulin G antibodies (1:100; sc-372; Vector 
Laboratories, Inc., Burlingame, CA, USA) for 30 min at room temperature. The slides 
were washed with PBS and avidin/biotin complex methods were performed (PK-4000; 
Vector Laboratories, Inc.) for 30 min. The tissue sections were counterstained with 
histogreen and then stained with nuclear fast red. 
     For the TUNEL staining, 3- m tissue sections were placed on glass slides and 
deparaffinized, then washed with ethanol and water and soaked in diluted water. The 
TUNEL staining was performed using an In situ Apoptosis Detection kit (Takara Bio, 
Inc., Shiga, Japan) according to the manufacturer's instructions. The tissue sections 
were counterstained with histogreen and then stained with nuclear fast red. A total of 
10 random high power fields were selected and the number of positive cells was 
counted. 
2.4 Image analysis of HE and Ki 67 staining
     An analysis of the necrotic regions was performed using the bio imaging 
analysis system (Lumina Vision; Mitani Corporation, Tokyo, Japan). The necrotic 
regions were assessed based on the inhibition of cytoplasm, denaturation and nuclear 
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fragmentation. In brief, the images of 10 randomly chosen high power fields 
(magnification, x200) in each cross section were captured using a digital camera 
attached to an Olympus microscope system (Olympus Corporation, Tokyo, Japan). 
The proportion of the necrotic areas among the total area was calculated. All the 
tumor tissues were analyzed. The mean proportion of the necrotic areas was 
calculated. 
     With regard to the Ki 67 staining, a quantitative digital morphometric analysis of 
the Ki 67 positive areas was performed. In brief, the images of 10 randomly chosen 
high power fields (magnification, x200) in each cross section were captured using a 
digital camera attached to an Olympus microscope system (Olympus Corporation). 
The color wavelengths of the copied image were transformed into digital readings 
using the Lumina Vision software program (Mitani Corporation), allowing for the 
quantification of the various color wavelengths, with pixels as the unit of measurement. 
The proportion of the positive areas in the tumor tissues was calculated by dividing 
the total pixel area of the positive areas by the total pixel area that corresponded with 
the total tumor tissue in the field of view. The tumor tissues of three mice in each 
group were analyzed. The mean proportion of the positive areas in 30 fields was 
calculated in each group. 
2.5 Statistical analysis 
The data are expressed as the mean ± SE. The statistical analyses were 
performed using one-way ANOVA, followed by Tukey Kramer's test. P<0.05 was 
considered to indicate a statistically significant difference. 
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3. Results 
3.1 Effects of PHT on tumor growth
The tumor growth rates are shown in Fig. 1. In the PHT group (93.6±5.7 
mm3/day), the growth rates of the tumor tissues were significantly decreased 
compared with those observed in the ICG (175.4±16.5 mm3/day), light (142.0±6.3 
mm3/day) and control (184.8±13.0 mm3/day) groups (P<0.05). 
3.2 Histological observations 
     In the PHT group, uniform, large necrotic regions were observed at the tumor 
margin on the skin side. By contrast, numerous foci of necrosis were observed in the 
light group, primarily at the tumor margin on the skin side. Among the necrotic areas, 
no immunocytes, including lymphocytes or neutrophils, were observed in any of the 
groups. 
     The proportions of the necrotic areas are shown in Fig. 2. The values in the PHT 
(40.0±9.1%) and light (37.0±11.4%) groups were increased significantly compared 
with those observed in the ICG (5.0±2.3%) and control (5.0±1.8%) groups. However, 
there were no significant differences between the PHT and light groups. 
3.3 Immunohistological analysis 
The results of the Ki 67 immunohistochemistry are shown in Fig. 3. The 
proportions of the Ki 67 positive areas in the PHT (29.0±1.6%/field) and light 
(20.1±6.1%/field) groups were less than those observed in the ICG (51.6±1.7%/field) 
and control (35.4±8.9%/field) groups. In the light group, the proportion of the 
Chapter 
Ki 67 positive areas was significantly decreased compared with that observed in the 
ICG group (P<0.05). 
     The results of the TUNEL immunohistochemistry are shown in Fig. 4. The 
number of TUNEL positive cells (85.5±16.9 cells/field) in the PHT group was 
increased significantly compared with that observed in the other groups. In the ICG 
and control groups, almost no TUNEL positive cells were observed in the tumor 
tissues. In the light group, TUNEL positive cells were observed in the tumor tissues 
(3.0±2.3 cells/field).
4. Discussion 
     In the present study, PHT was observed to be effective in vivo and in vitro. The 
tumor growth rate in the PHT group was decreased significantly compared with that 
observed in the other groups. It has been reported that the combination of ICG and a 
805 nm diode laser exhibits anticancer efficacy in vivo and in vitro (Chen et al., 1995a; 
Chen et al., 1995b; Chen et al., 1996; Ito et al., 2004). In these studies, it was 
speculated that ICG generated heat in response to light near the 800 nm wavelength, 
which indicated hyperthermia. In the present study, a broadband light source was 
used instead of a diode laser in the PHT group, as ICG generates active oxygen in 
response to light at 600 800 nm (photodynamic effect) in addition to hyperthermia 
(Abels et al., 1998; Bäumler et al., 1999; Bozkulak et al., 2009; Hirano et al., 2006). 
The present results revealed that PHT is more effective in suppressing tumor growth 
compared with hyperthermia alone. 
     Histologically, the proportion of the necrotic areas was similar between the PHT 
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and light groups. This indicates that hyperthermia alone induces tumor necrosis. With 
regard to the tumor growth rates, the rate that was observed in the PHT group was 
significantly decreased compared with the rate that was measured in the light group, 
indicating that the tumor cells in the areas without necrosis in the PHT group 
proliferated slowly compared with those in the light group. 
     The slow proliferation of tumor cells implies that numerous tumor cells do not 
proliferate due to causes such as cell cycle arrest and apoptosis. The present study 
investigated cell cycle arrest and apoptosis using immunohistochemical methods. 
TUNEL staining is one method that is used to detect apoptosis (Allen et al., 1997; 
Otsuki et al., 2003). The present results revealed that the number of TUNEL-positive 
cells was greater in the PHT group than in the light group. This result indicates that 
PHT strongly induces apoptosis compared with hyperthermia. Ki-67 is a cell 
population marker that is detected during all the active phases of the cell cycle, but is 
absent in resting cells (Brown & Gatter, 2002). With regard to Ki-67 staining, the 
proportions of the Ki-67-positive areas in the PHT and light groups were less than 
those observed in the ICG and control groups, which indicates that PHT and 
hyperthermia induce cell cycle arrest. However, there were no significant differences 
between the PHT and light groups. Our previous data has shown that PHT induces 
cell cycle arrest at an early time following the treatment (Radzi et al., 2012b). The 
present results do not support our previous data. One reason for this discrepancy may 
be differences in the sampling time following the treatment. In the present study, the 
samples were obtained at nine days post-treatment. Periodical sampling (days 1, 3, 5 
and 7) following treatment is therefore required in future studies. 
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     Tumor cells are more sensitive to heat under acidic conditions (Gerweck, 1977). 
Therefore, saline that was adjusted to pH 5.0 using acetic acid was used as a solvent 
for ICG. In a preliminary experiment, saline that was adjusted to a pH of 4.0 was 
observed to induce inflammation in the tissue. 
     In the present study, single treatments were performed, following which, tumor 
growth was observed. Consequently, it was identified that the single treatments were 
not adequate to induce complete tumor remission. In order to achieve complete 
remission, several rounds of treatment are necessary. Further studies are therefore 
required. 
     In conclusion, the growth rates of the tumor tissues were significantly decreased 
in the PHT group. Necrosis and apoptosis were induced by the PHT treatment. The 
Ki-67-positive areas were significantly decreased by the PHT treatment. The data 
indicate the PHT has the potential to be a novel cancer treatment. Further studies 
using clinical patients are required. 
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Figures 
Figure 1. Effects of photodynamic hyperthermal therapy (PHT) on tumor growth. The 
tumor volume was measured on days 0 and 9. The tumor growth rates (mm3/day) 
were calculated according to the tumor volumes. The data are presented as the mean 
± SE of each group. Statistical significance was determined according to the 
Tukey Kramer test. **P<0.01 and *P<0.05. ICG, indocyanine green. 
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Figure 2. Effects of photodynamic hyperthermal therapy (PHT) on the proportion of 
necrotic areas in the tumor tissue. The proportions of necrotic areas were calculated. 
The data are presented as the mean ± SE of each group. Statistical significance was 
determined according to the Tukey Kramer test. **P<0.01. ICG, indocyanine green. 
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Figure 3. Effects of photodynamic hyperthermal therapy (PHT) on the proportion of 
Ki 67 positive areas in the tumor tissue. The proportions of Ki 67 positive areas 
were calculated. The data are presented as the mean ± SE of each group. Statistical 
significance was determined according to the Tukey Kramer test. *P<0.05. ICG, 
indocyanine green. 
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Figure 4. Effects of photodynamic hyperthermal therapy (PHT) on the number of 
terminal deoxynucleotidyltransferase mediated dUTP nick end labeling 
(TUNEL)-positive cells in the tumor tissue. The numbers of TUNEL positive cells 
were calculated. The data are presented as the mean ± SE of each group. Statistical 




Photodynamic hyperthermal chemotherapy with indocyanine green: 
a novel cancer therapy for 16 cases of malignant soft tissue sarcoma 
Abstract 
     Sixteen cases of malignant soft tissue sarcoma (STS; 10 canines and six 
felines) were treated with a novel triple therapy that combined photodynamic therapy, 
hyperthermia using indocyanine green with a broadband light source, and local 
chemotherapy after surgical tumor resection. This triple therapy was called 
photodynamic hyperthermal chemotherapy (PHCT). In all cases, the surgical margin 
was insufficient. In one feline case, PHCT was performed without surgical resection. 
PHCT was performed over an interval of 1 to 2 weeks and was repeated three to 21 
times. No severe side effects, including severe skin burns, necrosis, or skin suture 
rupture, were observed in any of the animals. No disease recurrence was observed in 
seven out of 10 (70.0%) dogs and three out of six (50.0%) cats over the follow-up 
periods ranging from 238 to 1901 days. These results suggest that PHCT decreases 
the risk of STS recurrence. PHCT should therefore be considered an adjuvant therapy 
for treating companion animals with STS in veterinary medicine. 
1. Introduction 
     Soft tissue sarcoma (STS) develops in a variety of mesenchymal tissues (Kuntz 
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et al., 1997). In general, local recurrence is common following conservative excision. 
Therefore, other therapies including radiation therapy and chemotherapy are used to 
prevent recurrence after performing a wide first excision (Ettinger, 2003; Liptak & 
Forrest, 2012; McChesney et al., 1986; Ogilvie et al., 1989; Ogilvie et al., 1991). 
Radiation therapy plays a particularly important role in the management of STS 
(Dernell, et al., 1998). However, this type of therapy can only be performed in 
restricted facilities. Some patients cannot undergo radiation therapy due to financial 
difficulties or because the number of available facilities is limited. Therefore, it is 
necessary to develop novel and effective techniques to treat STS. 
     Indocyanine green (ICG) induces heat generation in response to light at a 
wavelength of 808 nm (Chen et al., 1995a; Chen et al., 1995b; Chen et al., 1996) and 
oxygen radicals upon exposure to light at wavelengths of 600 800 nm (Hirano et al., 
2006). Based on these evidences, we developed a novel cancer therapy using the 
properties of ICG and a broadband light source instead of a diode laser to establish a 
combination of photodynamic therapy and hyperthermia. This method is known as 
photodynamic hyperthermia (PHT) and can be combined with local chemotherapy to 
create a triple therapy strategy (photodynamic therapy, hyperthermia therapy, and 
chemotherapy) called photodynamic hyperthermal chemotherapy (PHCT). To date, no 
studies on the application of PHT and PHCT for the treatment of STS have been 
published. This is the first report of the use of PHCT to treat STS. 
2. Materials and Methods 
2.1 Animals 
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     Table 1 presents a summary of the 10 canine and six feline cases. These 
animals were treated at Veterinary Teaching Hospital of Tottori University (six dogs 
and four cats; Tottori, Japan), Takayama Pet Clinic (two dogs; Osaka, Japan), Aino 
Animal Hospital (one dog and two cats; Shizuoka, Japan) and Tokyo Animal Medical 
Center (one dog; Tokyo, Japan), respectively. The animals were diagnosed with STS 
based on preoperative biopsies. The ages of the animals ranged from 4 to 15 years. 
The dogs included two Labrador retrievers, two Golden retrievers, one Cocker spaniel, 
one Welsh corgi, one Miniature schnauzer, one French bulldog, and two Mongrels. 
The cats included five Domestic shorthair (DSH) cats and one American shorthair. We 
measured the original tumor size by caliper before surgery. All cases were classified 
according to TNM (T, size of the primary tumor; N, condition of the regional lymph 
nodes; M, absence/presence of distant metastasis) stage (Liptak & Forrest, 2012). 
Tumors in five dogs and six cats 
greatest dimension), and T2 (> 5 cm in diameter at greatest dimension) in five dogs. 
     Among the dogs, the tumor types included three cases of malignant 
schwannoma, three cases of hemangiopericytoma, one case of liposarcoma, one 
case of fibrosarcoma, and two cases of undifferentiated soft tissue tumors. In the cats, 
the tumor types included three cases of fibrosarcoma, one case of malignant 
schwannoma, one case of rhabdomyosarcoma, and one case of an undifferentiated 
soft tissue tumor. The tumor sites included the trunk in four cases (one in the dorsal 
region, two in the axilla, and one in the perineum) and the limbs in 12 cases. No lung 
metastasis was observed by radiography in any case. 
     We explained the risk of recurrence and treatment options, including surgery, 
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radiation, and chemotherapy, to the animal owners. When tumors had developed in 
the limbs, we proposed amputation as the first choice of treatment to the owners. 
However, the owners did not desire amputation and radiation. We then proposed to all 
owners other treatments including the combination of PHCT and surgery. We 
explained that PHCT is an experimental therapy, and all owners of the pets enrolled in 
this clinical trial provided informed consent. 
2.2 Surgical treatment 
     For tumors that had developed in the limbs, we maintained sufficient skin for 
skin closure with skin sutures after the tumors were removed because the owners did 
not want us to perform reconstructive surgery such as skin grafting. As a result, we 
could not obtain sufficient surgical margins. We removed the underlying fascia of the 
tumors. In some cases, we could not perform perfect skin closure due to the presence 
of skin ulcers (Fig. 1A). In some cases (cases C06, C09, and F04), we removed the 
tumors with an ultrasonic aspiration device (Qucer; M & M, Japan). For case F02, only 
PHCT was performed because the owner did not wish the animal to undergo surgery. 
2.3 PHCT 
     ICG (25 mg/vial, Giagnogreen; Daiich Sankyo, Japan) was dissolved in 9 ml of 
saline with an adjusted pH of 5.0. As an anti-tumor drug, 1 ml of bleomycin (1 mg/ml, 
Buleo; Nippon Kayaku, Japan) or carboplatin (10 mg/ml; Nippon Kayaku) was added 
to the ICG solution. For some cases, a small volume (0.1 or 0.2 ml) of paclitaxel 
(Bristol-Myers Squibb, USA.) was added to the ICG solution. For one case (case C04), 
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no anti-
broadband light source (Super Lizer 5000; Tokyo Iken, Japan) emitting a wavelength 
spectrum from 600 to 1,600 nm with a 5,000 mW maximum output power was used 
because ICG responses to light at wavelength of 600 800 nm. 
     For each case, the tumors were resected and ICG solution was injected into the 
resected area 3-dimensionally, including the skin surgical margin (3 cm). One ml of 
the ICG solution was administered per cm2 of the wound bed. Irradiation was 
administered at a distance of 10 cm from the resected area (irradiation area: 113 cm2, 
40 mW/cm2) for 20 min per 113 cm2 (48 J/cm2; Fig. 1B) immediately after the ICG 
solution was injected. The temperature at the surface of the resected area was kept 
under 45  by moving light source near and away from the skin surface and 
monitored with a thermometer. The first round of PHCT was performed immediately 
after skin suturing following surgery. The treatment interval between the second and 
fourth round of PHCT was generally 1 week, and then the treatment was performed at 
intervals of 2 to 4 weeks. At a minimum, treatment was continued for 3 months after 
surgery. At that point, we continued the treatment if the owner desired. For the second 
and subsequent rounds of PHCT, the treatments were performed with all animals 
under sedation. In some cases, local anesthesia was induced by Lidocaine of 15 50 
mg/head (Xylocaine; AstraZeneca, Japan). 
2.4 Follow-up after PHCT 
     In all cases, follow-up examinations for STS recurrence and metastasis were 
performed at intervals of several months for 1 year after the first round of PHCT. 
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Thereafter, follow-up examinations were performed once a year for 5 years. 
3. Results 
     Table 2 presents a summary of the study results. PHCT was performed three to 
21 times. The treatment frequency depended on the wishes of the owner. No severe 
side effects, including severe skin burns, necrosis, or rupture of skin sutures, were 
observed in any of the animals although skin redness and minor skin burns occurred. 
The overall canine survival time (ST) except for 1 case of amputation (case C06) 
ranged from 225 to 1,901 days (median survival time: 767 days). In seven out of 10 
dogs (70.0%), no recurrence was observed during the follow-up periods ranging from 
238 to 1,901 days. In five of these seven dogs, no recurrence was observed after 
more than 2 years. The remaining three dogs (two with undifferentiated soft tissue 
sarcomas and one with liposarcoma) experienced recurrence or metastasis over 
intervals ranging from 72 to 162 days after surgery. One case with liposarcoma (case 
C06) experienced local recurrence occurring within 1 month after the first surgery. In 
this animal, local recurrence was also observed 72 days after the first round of PHCT 
following the second surgery. The disease-free time (DFT) was prolonged by the use 
of PHCT. However, amputation was perfor
and the dog is currently alive. One dog (case C08) of the remaining three dogs died 
due to tumor progression. In case 08, metastasis to the sublumbar lymph nodes was 
observed. In that animal, no local recurrence was found. In case C09, local 
recurrence was observed 162 days after the first round of PHCT. PHCT was repeated 
for this animal five times at intervals of 1 to 2 weeks. Thereafter, the dog was only 
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followed up. Sixty-seven days after the fifth round of PHCT, local recurrence was 
observed. The dog eventually died of cardiac failure 225 days after the first round of 
PHCT. 
     The overall feline ST, excluding two cases of amputation (cases F04 and F06), 
ranged from 383 to 1,521 days (median survival time: 1,344 days). In three out of the 
six cats (50.0%), no recurrence was observed over the follow-up periods ranging from 
1,173 to 1,521 days. The remaining three cats (one case of fibrosarcoma, one case of 
rhabdomyosarcoma, and one case of undifferentiated STS) experienced recurrence 
over intervals ranging from 20 to 175 days after surgery. In two (cases F04 and F06) 
out of the remaining three cases, amputation was performed on one cat (case F04) 
that is currently alive and one cat (case F06) that died due to unknown cause. The 
remaining cat died due to tumor progression. In case F02 for which no surgery was 
performed, we periodically assessed tumor status using fine needle aspiration (FNA). 
No living tumor cells were observed by FNA during the eighth round of PHCT. We 
diagnosed the tumor as degenerative following PHCT, and the degenerative tumor 
tissue was removed using an ultrasonic aspiration device (Sono Cure; Tokyo Iken, 
Japan). Thereafter, PHCT was performed for 3 months. This cat had no recurrence for 
about 5 years. 
4. Discussion 
     Malignant STSs rarely metastasize; however, they are locally invasive (Bostock 
& Dye, 1980). If the surgical margin is insufficient, the rate of recurrence is 10 times of 
that when the surgical margin is sufficient (Kuntz et al., 1997). Therefore, complete 
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resection with a sufficient surgical margin is necessary. In general, adjuvant therapies 
including radiation therapy and chemotherapy are administered to cases of 
insufficient surgical margins (Ettinger, 2003; Liptak & Forrest, 2012; McChesney et al., 
1986; Ogilvie et al., 1991). In particular, radiation therapy plays an important role in 
the management of STS. In the present study, the surgical margins were insufficient in 
all cases. However, 70.0% (7/10) of the dogs and 50.0% (3/6) of the cats did not 
experience recurrence over follow-up periods ranging from 238 to 1,901 days. These 
results suggest that PHCT decreases the risk of recurrence. 
     As an alternative to radiation therapy, we developed a new therapy, PHT, by 
combining Photodynamic therapy (PDT) and hyperthermia with ICG using a 
broadband light source. Furthermore, we administered PHT in combination with local 
demonstrated the efficacy of the combination of ICG and use of a broadband light 
source in cancer therapy. 
     It has been suggested that fibrosarcomas, malignant schwannomas, and 
hemangiopericytomas are sensitive to PHCT considering the relationship between 
tumor type and PHCT efficacy. The local control rate of fibrosarcoma, malignant 
schwannoma, and hemangiopericytoma was 100% in the present study. However, 
PHCT is not effective for other tumor types including liposarcoma, 
rhabdomyosarcoma, and undifferentiated STSs occurring in the limbs. In these cases, 
the tumors recurred ranging from 20 to 175 days after the first PHCT. These results 
suggest that the effects of PHCT might differ depending on tumor type. Further 
investigation into this possibility is necessary. In the present study, no relationship 
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between treatment frequency and recurrence was observed. In one case (case C09), 
local recurrence was observed 63 days after the final round of PHCT. This 
phenomenon suggests that it is important to periodically continue treatment with 
PHCT. Additionally, no relationship was observed between the use of anti-cancer 
drugs and outcomes. 
     In two out of three canine and two out of three feline recurrence cases, the 
tumor cells had infiltrated deeply. We speculate that the light used for PHCT did not 
reach the tumor cells located in deep tissues. In a preliminary experiment, we found 
that the temperature at a depth of 2 cm from the skin surface did not reach 40  (data 
not shown), indicating that PHCT is not effective for treating tissues beyond this depth. 
Additionally, the ICG solution was not equally distributed. These drawbacks will be 
investigated in the future. 
     Hyperthermia is not a common treatment in veterinary medicine because the 
required device is expensive and few fundamental data related to the efficacy of 
hyperthermia are available. On the other hand, there are reports of PDT being used to 
treat spontaneous tumors in canines and felines, and the efficiency of this technique 
has been recognized (Dougherty et al., 1981; Okamoto et al., 2005; Osaki et al., 
2009; Peaston et al., 1993; Reeds et al., 2004; Roberts et al., 1991; Tanabe et al., 
2004). However, the photosensitizer for PDT is very expensive and a special diode 
laser is needed. Therefore, PDT is also rarely administered by veterinarians. ICG was 
developed as a drug to promote liver and bile duct function, and it has been used 
medically since 1956. This drug is safe for both human and animals (Cherrick et al., 
1960). In particular, ICG is widely used in ophthalmology for hyperthermia therapy 
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with an 808-nm diode laser to treat chorioretinopathy (Dzurinko et al., 2004). ICG is 
also used for sentinel biopsies (Hirche et al., 2010; Hojo et al., 2010). 
     Some reports have suggested that ICG induces the formation of oxygen radicals 
(Abels et al., 1998; Bäumler et al., 1999; Bozkulak et al., 2009; Diven et al., 1996; 
Mamoon et al., 2009). Most of these findings are from in vitro studies of different 
human cell lines. Bozkulak et al. (Bozkulak et al., 2009) reported that ICG with 
near-infrared light (809 nm, 60 mW/cm2, 24 J/cm2) is very effective for eliminating 
human breast cancer cells. In this study, the temperature of the medium was 
controlled to ensure that it remained at 37 . The authors concluded that ICG acts as 
a new photosensitizer. Hirano et al. (Hirano et al., 2006) was the first to demonstrate 
that ICG induces the formation of oxygen radicals in response to irradiation with light 
at a wavelength of 600 800 nm. The concentration of oxygen radicals produced by 
ICG dissolved in ethanol is similar to that generated by other photosensitizers. 
Oxygen radicals are formed even if ICG is dissolved in water although the 
concentration is lower. The total volume of oxygen radicals produced is thought to 
result from the accumulation of oxygen radicals produced with each wavelength. 
Therefore, a broadband light emitting light over a range of 600 800 nm would induce 
the formation of more oxygen radicals than a diode laser. Additionally, a broadband 
light that has an emission range of 600 800 nm would stimulate ICG to 
simultaneously induce heat and oxygen radical production in tumor tissues. 
     We previously investigated the effects of PHT on B16F10 murine melanoma 
cells in vitro (Radzi et al., 2012a; Radzi et al., 2012b). Our results demonstrated that 
PHT induces early morphological changes in tumor cells that promote more cell death 
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than hyperthermia alone. Furthermore, PHT induces early apoptosis and cell arrest. 
These in vitro data support the present in vivo results. 
     Tumor cells are more sensitive to heat under acidic conditions (Gerweck, 1977). 
Therefore, saline with a pH adjusted to 5.0 with acetic acid was used as a solvent for 
ICG. In a preliminary experiment, we found that saline with a pH of 4.0 induced tissue 
inflammation (data not shown). 
     The effects of anti-tumor drugs are enhanced by heat (Hahn et al., 1975; Hahn, 
1979; Marmor, 1979; Newell & Tannock, 1989). Furthermore, tumor tissues have a 
tendency to be acidic (Wike-Hooley et al., 1985). Therefore, we selected bleomycin as 
an anti-tumor drug because it is effective in acidic environments (Hahn et al., 1975). 
Platinum-based drugs such as cisplatin and carboplatin are also useful anti-tumor 
reagents. In the present study, we were concerned that PHCT would affect the 
stability of the anti-tumor drug. However, our preliminary data showed that the 
anti-tumor effects of PHCT were enhanced by the addition of an anti-tumor drug (data 
not shown). This means that PHCT does not only affect the stability of the anti-tumor 
drug but also enhances its effects. 
     In conclusion, PHCT is a simple procedure, is not associated with any severe 
side effects, and requires no special facilities. However, further investigation is 
necessary to establish PHCT as a therapeutic technique due to some associated 
problems involving treatment times and intervals, and selection of anti-cancer drugs. 
Nevertheless, this modality is expected to become a useful alternative to radiation 
therapy for treating superficial tumors such as STS in companion animals. 
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Fig. 1. (A) Skin incision (arrow) in case C07. (B) PHCT was performed after surgery. 
The arrow indicates the broadband light source while the arrowheads indicate the 






PHT has an anticancer efficacy in a tumor-bearing mouse model . 
PHCT is expected to become a useful alternative to radiation therapy for 
superficial tumors such as STS in companion animals.  
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